NCT00006721 2026-03-16
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
Clinical Trials
9 trialsNCT00479167 2021-11-04
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Rush University Medical Center
Phase 2 Terminated
NCT00770224 2019-08-28
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00004874 2018-01-17
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Terminated
NCT01389076 2017-01-30
Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00319332 2015-04-17
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
GlaxoSmithKline
Phase 3 Withdrawn
NCT00073931 2015-02-05
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00003784 2013-01-24
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00475332 2012-02-15
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
University of Florida
Phase 2 Terminated